SEQUENCE LISTING PATE <110> Max-Delbrueck-Centrum fuer Molekulare Medizin RECEIVED <120> Tumor vaccines for mucl-positive carcinomas SEP 1 9 2002 <130> 0107-027 TECH CENTER 1600/2900 <140> Ser. No. 09/606,910 <141> 2000-06-29 <150> DE 197 58 400.4 <151> 1997-12-30 <150> PCT/DE98/03819 <151> 1998-12-30 <160> 6 <170> PatentIn Ver. 2.1 <210> 1 <211> 7 <212> PRT <213> human <220> <223> immunodominant region of MUC1 <400> 1 Pro Asp Thr Arg Pro Ala Pro 1 5 <210> 2 <211> 8 <212> PRT <213> mouse, IgG1 <220> <223> A76-A/C7 epitope <400> 2 Ala Pro Asp Thr Arg Pro Ala Pro 1 5 <210> 3 <211> 6 <212> PRT <213> mouse, IgG1 <220> <223> MFO6 epitope

```
<400> 3
Asp Thr Arg Pro Ala Pro
   1
 <210> 4
 <211> 21
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: designed
       synthetical glycopeptide
 <400> 4
 Ala His Gly Val Thr Ser ala Pro Asp Thr Arg Pro Ala Pro Gly Ser
   1
                                                           15
               · 5
                                       10
 Thr Ala Pro Pro Ala
              20
 <210> 5
 <211> 20
 <212> PRT
 <213> Artificial Sequence
 k220>
 <223> Description of Artificial Sequence: designed
       synthetical glycopeptide
 <400> 5
 His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr
 · 1
                   5
                                       10
                                                           15
 Ala Pro Pro Ala
              20
 <210> 6
 <211> 7
 <212> PRT
 <213> human
 <220>
 <221> DOMAIN
 <222> (1)..(7)
 <223> immunodominant motif of the epithelial mucin (
       MUC1)
 <400>_6
 Pro Asp Thr Arg Pro Ala Pro
   1
                   5
```